Table 1.
Major Trials Evaluating Direct-Acting Antiviral Agents in the Treatment of Post-Liver Transplant HCV Recurrence
| Study | Genotype, n (%) | Severity of liver disease, n (%) | Treatment | Duration | SVR12 by Genotype, n (%) | SVR12 by Severity, n (%) |
|---|---|---|---|---|---|---|
| Charlton23,a | 1a: 22 (55) 1b: 11 (28) 3: 6 (15) 4: 1 (3) |
F0: 1 (3) F1-2: 14 (35) F3: 9 (23) F4: 16 (40) |
Sofosbuvir + ribavirin | 24 weeks | 1a: 16 (73) 1b: 6 (55) 3: 6 (100) |
F0: 1 (100) F1-2: 10 (71) F3: 7 (78) F4: 10 (63) |
| Forns24,a | 1a: 36 (35) 1b: 49 (47) 2: 1 (1) 3: 7 (7) 4: 7 (7) Multiple: 4 (4) |
All patients had either aggressive recurrent disease or cirrhosis | Sofosbuvir + ribavirin | 24-48 weeks |
N/A | Early recurrence: 35 (73) Cirrhosis: 19 (43) |
| Charlton26,b | 1a: 164 (72) 1b: 63 (28) 4: 2 (1) |
No cirrhosis: 111 (48) CTP A: 51 (22) CTP B: 52 (23) CTP C: 9 (4) FCH: 6 (3) |
Sofosbuvir + ledipasvir + ribavirin | 12 weeks | N/A | No cirrhosis: 53 (96) CTP A: 25 (96) CTP B: 22 (85) CTP C: 3 (60) FCH: 4 (100) |
| 24 weeks | N/A | No cirrhosis: 55 (98) CTP A: 24 (96) CTP B: 23 (88) CTP C: 3 (75) FCH: 2 (100) |
||||
| Saab27,a | 1: all patients | F0: 13 (46) F1: 2 (7) F2: 2 (8) F3: 6 (23) F4: 5 (19) |
Sofosbuvir + simeprevir | 12 weeks | N/A | Overall SVR12: 28 (93) |
| Pungpapong28,a | 1a: 74 (60) 1b: 43 (35) Unclear: 6 (5) |
F0-2: 85 (70) F3-4: 37 (30) |
Sofosbuvir + simeprevir ± ribavirin | 12 weeks | 1a: 64 (86) 1b: 41 (95) |
F0-2: 67 (81) F3-4: 34 (93) |
| Gutierrez29,a | 1a: 35 (57) 1b: 26 (43) |
F0-2: 38 (62) F3-4: 23 (38) |
Sofosbuvir + simeprevir ± ribavirin | 12 weeks | 1a: 31 (89) 1b: 26 (100) |
F0-2: 38 (100) F3-4: 19 (83) |
| Kwo34,b | 1a: 29 (85) 1b: 5 (15) |
F0: 6 (18) F1: 13 (38) F2: 15 (44) |
Ombitasvir + paritaprevir with ritonavir + dasabuvir | 24 weeks | 1a: 28 (97) 1b: 5 (100) |
N/A |
| Poordad33,c | 1a: 31 (58) 1b: 10 (19) 3: 11 (21) 6: 1 (2) |
F0-2: 23 (43) F3: 13 (25) F4: 16 (30) Not reported: 1 (2) |
Sofosbuvir + daclatasvir + ribavirin | 12 weeks | 1a: 30 (97) 1b: 9 (90) 3: 10 (91) 6: 1 (100) |
N/A |
CTP, Child-Turcotte-Pugh; FCH, fibrosing cholestatic hepatitis; HCV, hepatitis C virus; SVR, sustained virologic response.
a
Real-life cohort.
b
Phase 2 trial.
c
Phase 3 trial.